Phase III evaluation of once-daily, oral therapy with ICL670 (Exjade (R)) versus deferoxamine in patients with beta-thalassemia and transfusional hemosiderosis
Yazar
Janka-Schaub, G
Alberti, D
Giardina, P
Opitz, H
Ressayre-Djaffer, C
Cappellini, M
Bejaoui, M
Perrotta, S
Agaoglu, L
Kattamis, A
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Bildiri [64839]